The stock price of Royalty Pharma plc (NASDAQ: RPRX) has dropped by -1.59 compared to previous close of 31.37. Despite this, the company has seen a fall of -8.53% in its stock price over the last five trading days. marketbeat.com reported 2025-03-29 that The American stock markets have had a rough month as investors remain jittery over international tariff fears. While this market downturn has affected most sectors of the economy, healthcare stocks are doing exceptionally well, outperforming the general market as the most successful sector of 2025 so far.
Is It Worth Investing in Royalty Pharma plc (NASDAQ: RPRX) Right Now?
The price-to-earnings ratio for Royalty Pharma plc (NASDAQ: RPRX) is 16.10x, which is above its average ratio. Moreover, the 36-month beta value for RPRX is 0.49. Analysts have varying opinions on the stock, with 5 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for RPRX is 334.29M and currently, short sellers hold a 4.66% of that float. On March 31, 2025, RPRX’s average trading volume was 4.37M shares.
RPRX’s Market Performance
The stock of Royalty Pharma plc (RPRX) has seen a -8.53% decrease in the past week, with a -8.23% drop in the past month, and a 21.54% gain in the past quarter. The volatility ratio for the week is 3.44%, and the volatility levels for the past 30 days are at 2.21% for RPRX. The simple moving average for the past 20 days is -6.01% for RPRX’s stock, with a 8.46% simple moving average for the past 200 days.
Analysts’ Opinion of RPRX
Many brokerage firms have already submitted their reports for RPRX stocks, with UBS repeating the rating for RPRX by listing it as a “Neutral.” The predicted price for RPRX in the upcoming period, according to UBS is $28 based on the research report published on June 03, 2024 of the previous year 2024.
UBS, on the other hand, stated in their research note that they expect to see RPRX reach a price target of $47. The rating they have provided for RPRX stocks is “Buy” according to the report published on June 14th, 2022.
Scotiabank gave a rating of “Sector Outperform” to RPRX, setting the target price at $53 in the report published on May 13th of the previous year.
RPRX Trading at -4.76% from the 50-Day Moving Average
After a stumble in the market that brought RPRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -9.74% of loss for the given period.
Volatility was left at 2.21%, however, over the last 30 days, the volatility rate increased by 3.44%, as shares sank -8.54% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +0.06% upper at present.
During the last 5 trading sessions, RPRX fell by -8.24%, which changed the moving average for the period of 200-days by +12.95% in comparison to the 20-day moving average, which settled at $32.85. In addition, Royalty Pharma plc saw 21.01% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for RPRX
Current profitability levels for the company are sitting at:
- 0.57 for the present operating margin
- 0.74 for the gross margin
The net margin for Royalty Pharma plc stands at 0.38. The total capital return value is set at 0.08. Equity return is now at value 12.75, with 4.96 for asset returns.
Based on Royalty Pharma plc (RPRX), the company’s capital structure generated 0.42 points at debt to capital in total, while cash flow to debt ratio is standing at 0.36. The debt to equity ratio resting at 0.74. The interest coverage ratio of the stock is 5.73.
Currently, EBITDA for the company is 1.29 billion with net debt to EBITDA at 3.64. When we switch over and look at the enterprise to sales, we see a ratio of 8.86. The receivables turnover for the company is 83.99for trailing twelve months and the total asset turnover is 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.44.
Conclusion
To wrap up, the performance of Royalty Pharma plc (RPRX) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
